Recent results from a pilot trial testing the ‘Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19’ (IMPACT-SIRIO 5; NCT04941105) demonstrate a survival benefit among adult patients.27 It is conceivable that such therapies will be trialed in other critically ill cohorts including sepsis and acute respiratory distress syndrome. The gene discussed is PCSK9; the disease is acute respiratory distress syndrome.